174 related articles for article (PubMed ID: 36632564)
1. Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer.
Wang F; Lu S; Cao D; Qian J; Li C; Zhang R; Wang F; Wu M; Liu Y; Pan Z; Wu X; Lu Z; Ding P; Li L; Lin J; Catteau A; Galon J; Chen G
Oncoimmunology; 2023; 12(1):2161167. PubMed ID: 36632564
[TBL] [Abstract][Full Text] [Related]
2. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
[TBL] [Abstract][Full Text] [Related]
3. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
Mlecnik B; Van den Eynde M; Bindea G; Church SE; Vasaturo A; Fredriksen T; Lafontaine L; Haicheur N; Marliot F; Debetancourt D; Pairet G; Jouret-Mourin A; Gigot JF; Hubert C; Danse E; Dragean C; Carrasco J; Humblet Y; Valge-Archer V; Berger A; Pagès F; Machiels JP; Galon J
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922789
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features Combined With Immune Infiltration Could Well Distinguish Outcomes in Stage II and Stage III Colorectal Cancer: A Retrospective Study.
Ren J; Xu L; Zhou S; Ouyang J; You W; Sheng N; Yan L; Peng D; Xie L; Wang Z
Front Oncol; 2021; 11():776997. PubMed ID: 34926285
[TBL] [Abstract][Full Text] [Related]
8. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer.
Kwak Y; Koh J; Kim DW; Kang SB; Kim WH; Lee HS
Oncotarget; 2016 Dec; 7(49):81778-81790. PubMed ID: 27835889
[TBL] [Abstract][Full Text] [Related]
9. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
10. Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment.
Wang F; Lu S; Zhou X; Di X; Wu R; Chen G; Tian S
Front Immunol; 2023; 14():1103741. PubMed ID: 37033948
[TBL] [Abstract][Full Text] [Related]
11. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
13. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
[TBL] [Abstract][Full Text] [Related]
15. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
17. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.
Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Marincola FM; Ascierto PA; Fox BA; Pagès F; Kawakami Y; Galon J
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139506
[TBL] [Abstract][Full Text] [Related]
18. CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review.
Fan X; Zhang J; Lu D
Medicine (Baltimore); 2023 Feb; 102(6):e32939. PubMed ID: 36820557
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a
Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P
Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.
Liang L; Zhu J; Jia H; Huang L; Li D; Li Q; Li X
Oncotarget; 2016 Jan; 7(1):1014-28. PubMed ID: 26510910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
